{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-172225","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2024-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.362614+00:00","generated_at":"2026-06-01T00:37:20.561847+00:00","sec_items":["2.05","5.02","7.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ovid Therapeutics cuts workforce by 43%, two executives depart","bullets":["Workforce reduced by 17 employees (~43% of headcount); one-time severance charge of ~$4.0M; substantially complete by Q3 2024.","General Counsel Thomas Perone and COO Jason Tardio depart effective July 11, 2024; consulting transition arrangements planned.","Cash runway extended into first half of 2026 due to cost savings from workforce reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-172225","json":"https://secwatch.observer/filing/0001193125-24-172225.json","markdown":"https://secwatch.observer/filing/0001193125-24-172225.md","text":"https://secwatch.observer/filing/0001193125-24-172225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000119312524172225/0001193125-24-172225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000119312524172225/d822326d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:37:20.561847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"57d7167a61","claim":"Jason Tardio departed as Chief Operating Officer at Ovid Therapeutics Inc..","evidence_excerpt":"Jason Tardio will cease serving as the Company’s Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312524172225/0001193125-24-172225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will cease serving"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"c35ca9453c","claim":"Thomas Perone departed as General Counsel, Chief Compliance Officer and Corporate Secretary at Ovid Therapeutics Inc..","evidence_excerpt":"on the Separation Date, Thomas Perone will cease serving as the Company’s General Counsel, Chief Compliance Officer and Corporate Secretary","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312524172225/0001193125-24-172225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will cease serving"},{"label":"Role","value":"General Counsel, Chief Compliance Officer and Corporate Secretary"}],"fact_type":"executive_change"},{"claim_id":"3041ca5455cf9f04fdcd059300dfad8594be27a9","claim":"Ovid Therapeutics Inc. announced a restructuring with charges of approximately $4.0 million (17 people, or approximately 43% of the Company's existing headcount).","evidence_excerpt":"of a general release of claims against the Company. The Company anticipates a one-time severance-related charge associated with the workforce reduction to be approximately $4.0 million, which represents cash expenditures related to employee severance and notice period payments, benefits and related costs that the Company expects to incur in connection with the","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312524172225/0001193125-24-172225-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $4.0 million"},{"label":"Headcount","value":"17 people, or approximately 43% of the Company's existing headcount"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}